You are here: Industry Insights > ER-004

News List

The EspeRare Foundation, Pierre Fabre to Develop XLHED Treatment americanpharmaceuticalreview
January 05, 2021
The EspeRare Foundation and the Pierre Fabre group have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia) ...
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004 prnasia
December 22, 2020
AGC Biologics announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder.
Global Respiratory Clinics Market will grow at a CAGR of 20.7% over the forecast period - says Absolute Markets Insights prnasia
December 14, 2020
The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic ...